US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

Equity Capital Markets

Sionna Therapeutics / Equity Capital Markets

<ul>
<li>Biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis opened its IPO 39% above issue.</li>
<li>The transaction was upsized from 8.8mm shares to 10.6mm shares and priced at the high-end of the range.</li>
<li>The IPOs that are more apt to see "follow-through" in the aftermarket are those with product candidates in later stage. This IPO does not meet that criteria. </li>
</ul>


Biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis opened its IPO 39% above issue.
The transaction was upsized from 8.8mm shares to 10.6mm shares and priced at the high-end of the range.
The IPOs that are more apt to see "follow-through" in the aftermarket are those with product candidates in later stage. This IPO does not meet that criteria. 


Sionna Therapeutics Inc. (SION): RA Capital Backed Biotech IPO Booms in Debut

<ul>
<li>The current price guidance is pointing to the high-end of the prevailing $16-$18 range with allocations expected to be "cut-back".</li>
<li>This biotech is extremely well-backed with RA Capital entering the IPO as the company's largest shareholder (29.2% pre-IPO stake).</li>
<li>Clinical-Stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients is set to go public on Friday. </li>
</ul>


The current price guidance is pointing to the high-end of the prevailing $16-$18 range with allocations expected to be "cut-back".
This biotech is extremely well-backed with RA Capital entering the IPO as the company's largest shareholder (29.2% pre-IPO stake).
Clinical-Stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients is set to go public on Friday. 


Sionna Therapeutics Inc. (SION): Biotech Guiding to High-End Pricing; Expecting Strong Outcome

<ul>
<li>Biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis filed for IPO.</li>
<li>The terms value the company between $652m-$734m with the $16-$18 price range.</li>
<li>The company's existing shareholders include some of the best pre-IPO names in the biotech sphere.</li>
</ul>


Biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis filed for IPO.
The terms value the company between $652m-$734m with the $16-$18 price range.
The company's existing shareholders include some of the best pre-IPO names in the biotech sphere.


Sionna Therapeutics, Inc. (SION): Phase I Cystic Fibrosis Biotech Sets Terms for IPO

United States

Clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Metsera (MTSR US)

Sionna Therapeutics Inc. (SION): RA Capital Backed Biotech IPO Booms in Debut

Biopharmaceutical company with potential cystic fibrosis treatment opens IPO above issue, but may not see strong aftermarket performance due to...

IPO Boutique

Sionna Therapeutics Inc. (SION): Biotech Guiding to High-End Pricing; Expecting Strong Outcome

Clinical-stage biopharmaceutical company backed by RA Capital set to go public with price guidance at high end of range, allocations expected to...

IPO Boutique

Sionna Therapeutics, Inc. (SION): Phase I Cystic Fibrosis Biotech Sets Terms for IPO

Biopharmaceutical company aiming to transform cystic fibrosis treatment seeks IPO, valued between $652m-$734m with strong pre-IPO investor backing.

IPO Boutique

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Sionna Therapeutics Inc. (SION): RA Capital Backed Biotech IPO Booms in Debut

​Biopharmaceutical company with potential cystic fibrosis treatment opens IPO above issue, but may not see strong aftermarket performance due to...

IPO Boutique

Sionna Therapeutics Inc. (SION): Biotech Guiding to High-End Pricing; Expecting Strong Outcome

​Clinical-stage biopharmaceutical company backed by RA Capital set to go public with price guidance at high end of range, allocations expected to...

IPO Boutique

Sionna Therapeutics, Inc. (SION): Phase I Cystic Fibrosis Biotech Sets Terms for IPO

​Biopharmaceutical company aiming to transform cystic fibrosis treatment seeks IPO, valued between $652m-$734m with strong pre-IPO investor backing.

IPO Boutique

Biopharmaceutical company with potential cystic fibrosis treatment opens IPO above issue, but may not see strong aftermarket performance due to...

Clinical-stage biopharmaceutical company backed by RA Capital set to go public with price guidance at high end of range, allocations expected to...

Biopharmaceutical company aiming to transform cystic fibrosis treatment seeks IPO, valued between $652m-$734m with strong pre-IPO investor backing.